Consultation on revised guideline on medicines to treat Alzheimer’s disease
Revised guideline is expected to facilitate development of more effective medicines
The European Medicines Agency (EMA) has released a revised guideline on medicines for the treatment of Alzheimer’s disease and other types of dementias for a six-month public consultation.
Stakeholders are invited to send their comments by 31 July 2016 to firstname.lastname@example.org using the template provided.
According to the World Health Organization, 35.6 million people have dementia worldwide and this number is expected to double by 2030.
Recent progress in understanding the pathophysiology of Alzheimer’s disease suggests that the biological changes associated with the disease start to occur as early as 10 to 20 years prior to the emergence of clinical symptoms. Experimental medicines should therefore be evaluated in earlier disease stages as certain treatments may be more effective at that stage than later in the illness.
EMA considers dementia as a key public health priority and follows a multi-stakeholder approach to facilitate research and development of more effective medicines. The revised guideline takes into account comments received at EMA’s workshop on the clinical investigation of medicines for the treatment of Alzheimer's disease in November 2014. This workshop brought together a wide range of stakeholders, including patient representatives, regulators, pharmaceutical industry and independent experts. The aim of the workshop was to ensure that during the revision of its guideline, EMA would be able to consider the most up-to-date scientific developments in understanding and treating Alzheimer’s disease and views from experts in the field. The revised guideline also builds on EMA scientific advice provided for a number of specific development plans for Alzheimer’s disease in recent years, as well as the qualification of several biomarkers for the selection of patients in clinical trials.
The revised guideline specifically addresses the:
- impact of new diagnostic criteria for Alzheimer’s disease, including early and even asymptomatic disease stages, on clinical trial design;
- choice of parameters to measure trial outcomes and the need for distinct assessment tools for the different disease stagesin Alzheimer’s (different signs and symptoms, differences in changes over time, severity);
- potential use of biomarkers and their temporal relationship with the different phases of Alzheimer’s disease at different stages of medicine development (mechanism of action, use as diagnostic test, enrichment of study populations, stratification of subgroups, safety and efficacy markers etc.);
- design of long-term efficacy and safety studies.
Comments received during the consultation will be taken into account in the finalisation of the guideline.
How useful is this page?
Average rating:Based on 5 ratings
Add your rating:
- See all ratings
1 ratings0 ratings0 ratings2 ratings2 ratings